Regeneron Pharmaceuticals' Change in Receivables fell 5653.65% to $51.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$498.1 million, marking a year-over-year decrease of 18990.97%. This contributed to the annual value of -$498.1 million for FY2025, which is 18990.97% down from last year.
According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Change in Receivables is $51.2 million, which was down 5653.65% from $80.3 million recorded in Q3 2025.
Regeneron Pharmaceuticals' Change in Receivables' 5-year high stood at $2.8 billion during Q2 2021, with a 5-year trough of -$1.5 billion in Q3 2021.
For the 5-year period, Regeneron Pharmaceuticals' Change in Receivables averaged around $80.7 million, with its median value being $69.3 million (2021).
Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 215403.09% in 2022, then surged by 1820000.0% in 2024.
Regeneron Pharmaceuticals' Change in Receivables (Quarter) stood at $584.5 million in 2021, then crashed by 137.57% to -$219.6 million in 2022, then soared by 137.66% to $82.7 million in 2023, then skyrocketed by 42.44% to $117.8 million in 2024, then tumbled by 56.54% to $51.2 million in 2025.
Its last three reported values are $51.2 million in Q4 2025, $80.3 million for Q3 2025, and $28.2 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value